文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

乳酸与白蛋白比值对重症急性胰腺炎合并急性肾损伤患者院内死亡率的预后价值:一项回顾性队列研究

Prognostic value of the lactate-to-albumin ratio for in-hospital mortality in severe acute pancreatitis with acute kidney injury: A retrospective cohort study.
PubMed 文献 · Am J Emerg Med · 2025-09-25
一句话结论在重症急性胰腺炎合并急性肾损伤患者中,乳酸与白蛋白比值(LAR)是院内死亡的独立预测因子,其判别能力优于单独使用乳酸或白蛋白。

该回顾性队列研究纳入2016年1月至2024年12月某三级医院收治的309例重症急性胰腺炎合并急性肾损伤患者,院内死亡率为24.9%。死亡组LAR显著高于存活组(0.94 vs. 0.59,P<0.001)。多变量分析显示LAR独立预测院内死亡(OR 1.33,95%CI 1.01-1.77,P=0.046),ROC分析显示LAR判别能力优于单独乳酸或白蛋白,Kaplan-Meier曲线显示高LAR组生存率显著降低(P<0.001),并发现LAR 0.69为死亡风险拐点。作者认为将LAR纳入临床评估可能改善早期风险分层并指导管理决策。

要点

  • 在309例重症急性胰腺炎合并急性肾损伤患者中,院内死亡率为24.9%,死亡组LAR为0.94,存活组为0.59(P<0.001)。
  • 多变量分析中LAR独立预测院内死亡(OR 1.33,95%CI 1.01-1.77,P=0.046)。
  • ROC分析显示LAR对院内死亡的判别能力优于单独使用乳酸或白蛋白。
  • Kaplan-Meier曲线显示高LAR组生存率显著低于低LAR组(P<0.001)。
  • LAR与死亡风险呈非线性关系,死亡风险拐点为LAR 0.69。

适用人群与场景

  • 2016年1月至2024年12月某三级医院收治的重症急性胰腺炎合并急性肾损伤患者309例。

研究设计与关键结果

  • 研究类型为回顾性队列研究,纳入309例重症急性胰腺炎合并急性肾损伤患者,总体院内死亡率为24.9%。
  • 死亡组LAR为0.94,存活组为0.59,死亡组显著高于存活组(P<0.001)。
  • 多变量分析显示LAR独立预测院内死亡(OR 1.33,95%CI 1.01-1.77,P=0.046)。
  • ROC分析显示LAR对院内死亡的判别能力优于单独使用乳酸或白蛋白。
  • Kaplan-Meier曲线显示高LAR组生存率显著降低(P<0.001)。
  • 平滑曲线拟合和两段线性回归发现LAR与死亡风险呈非线性关系,死亡风险拐点为LAR 0.69。
  • 亚组分析显示LAR与院内死亡的关联在各临床分层中一致。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为将LAR纳入临床评估可能改善重症急性胰腺炎合并急性肾损伤患者的早期风险分层并指导管理决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Severe acute pancreatitis (SAP) complicated by acute kidney injury (AKI) carries a high mortality risk, and reliable early prognostic markers are needed. This study investigated the prognostic value of the lactate-to-albumin ratio (LAR) for in-hospital mortality in SAP patients with AKI.

METHODS: We retrospectively analyzed 309 SAP patients with AKI admitted to a tertiary hospital between January 2016 and December 2024. Baseline demographics, laboratory data, and outcomes were collected. Logistic regression models identified independent risk factors for mortality. Receiver operating characteristic (ROC) curves, Kaplan-Meier survival analysis, and subgroup analyses evaluated the discriminative ability of LAR. Smooth curve fitting and two-piecewise linear regression assessed non-linear associations.

RESULTS: The overall in-hospital mortality was 24.9 %. Non-survivors had significantly higher LAR than survivors (0.94 vs. 0.59, P < 0.001). In multivariable analysis, LAR independently predicted in-hospital mortality (OR: 1.33; 95 % CI: 1.01-1.77; P = 0.046). ROC analysis showed LAR had superior discriminative ability compared with lactate or albumin alone. Kaplan-Meier curves demonstrated significantly reduced survival in patients with high LAR (P < 0.001). A non-linear relationship was identified, with a mortality risk inflection point at LAR 0.69. Subgroup analyses confirmed consistent associations across clinical strata.

CONCLUSION: LAR is an independent and practical biomarker for predicting in-hospital mortality in SAP patients with AKI, outperforming lactate and albumin alone. Incorporating LAR into clinical assessment may improve early risk stratification and guide management decisions.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhu Q, Geng P, Ling B, et al. Prognostic value of the lactate-to-albumin ratio for in-hospital mortality in severe acute pancreatitis with acute kidney injury: A retrospective cohort study. Am J Emerg Med. 2025. PMID: 41056810. doi:10.1016/j.ajem.2025.09.046

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。